Literature DB >> 8031031

Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

W V Kern1, E Andriof, M Oethinger, P Kern, J Hacker, R Marre.   

Abstract

Prophylactic treatment with fluoroquinolones of patients with profound neutropenia has been found to be useful for preventing gram-negative bacteremia and has become a standard preventive-therapy strategy in many cancer centers, but the development of bacterial resistance is a cause of concern. During the past few years, we have observed an increasing number of patients with leukemia from whom fluoroquinolone-resistant strains of Escherichia coli were isolated. The increase was significant in this patient population, and among patients with other underlying diseases, the rates of isolation of such strains per number of discharges were significantly lower and did not increase. Most of the leukemia case patients (16 of 19) had been pretreated with an oral quinolone (ofloxacin), with cumulative doses until the first isolation of a resistant E. coli strain ranging from 0 to 97.8 g (median, 14.4 g). Repeated isolation of such strains was seen in 8 of 17 patients during a follow-up period of > or = 4 weeks and in 1 of 6 patients during a follow-up period of > or = 16 weeks. Ten patients developed bacteremia (mortality, 1 of 10). On the basis of the number of patients with leukemia admitted to the hematology-oncology service, the incidence of bacteremia caused by fluoroquinolone-resistant E. coli increased from < 0.5% in 1988-1989 and 0.8% in 1990-1991 to 4.5% in 1992-1993 (P < 0.01). MICs for nine isolates obtained from cultures of blood from different patients ranged between 8 and 16 microgram/ml (ciprofloxacin and PD 131628), 8 and 32 microgram/ml (ofloxacin and BAY Y 3118), and 16 and 32 microgram/ml (sparfloxacin) and indicated resistance to trimethoprim-sulfamethoxazole, ampicillin, doxycycline, and chloramphenicol. Of nine isolates obtained from cultures of blood from different patients and that were subjected to genomic DNA typing by pulsed-field gel electrophoresis of XbaI digests, seven were typeable. Among these, four different genotypes were identified, suggesting both the independent development and the horizontal spread of resistant clones of E. coli.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031031      PMCID: PMC284525          DOI: 10.1128/AAC.38.4.681

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Norfloxacin resistance in a clinical isolate of Escherichia coli.

Authors:  H Aoyama; K Sato; T Kato; K Hirai; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

2.  Inactivation of quinolone by feces.

Authors:  J J van Saene; H K van Saene; C F Lerk
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

3.  Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens.

Authors:  C C Sanders; C Watanakunakorn
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

4.  Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.

Authors:  T Schmeiser; E Kurrle; R Arnold; M Wiesneth; D Bunjes; B Hertenstein; W Kern; W Heit; H Heimpel
Journal:  Scand J Infect Dis       Date:  1988

5.  Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli.

Authors:  K Sato; Y Inoue; T Fujii; H Aoyama; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

6.  Clinical isolate of Citrobacter freundii highly resistant to new quinolones.

Authors:  H Aoyama; K Fujimaki; K Sato; T Fujii; M Inoue; K Hirai; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

7.  Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers.

Authors:  D A Leigh; B Walsh; K Harris; P Hancock; G Travers
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

Review 8.  Antimicrobial prophylaxis in the neutropenic host: lessons of the past and perspectives for the future.

Authors:  L S Young
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

9.  Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia.

Authors:  G Maschmeyer; E Haralambie; W Gaus; W Kern; A W Dekker; H G De Vries-Hospers; W Sizoo; W König; F Gutzler; S Daenen
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

10.  Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.

Authors:  M Kresken; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

View more
  36 in total

Review 1.  Management of febrile neutropenia in low risk cancer patients.

Authors:  B A Oppenheim; H Anderson
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

2.  The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia.

Authors:  Bernard C Camins; Jonas Marschall; Shannon R DeVader; Dawn E Maker; Matthew W Hoffman; Victoria J Fraser
Journal:  J Hosp Med       Date:  2011 Jul-Aug       Impact factor: 2.960

3.  Posttreatment changes in Escherichia coli antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin.

Authors:  Shannon D Putnam; John W Sanders; David R Tribble; David R Rockabrand; Mark S Riddle; Patrick J Rozmajzl; Robert W Frenck
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

4.  Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.

Authors:  W V Kern; K Klose; A S Jellen-Ritter; M Oethinger; J Bohnert; P Kern; S Reuter; H von Baum; R Marre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

5.  Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.

Authors:  M Oethinger; A S Jellen-Ritter; S Conrad; R Marre; W V Kern
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

6.  Emergence and infectious complications of ciprofloxacin-resistant Escherichia coli in haematological cancer patients.

Authors:  M G van Kraaij; A W Dekker; E Peters; A Fluit; L F Verdonck; M Rozenberg-Arska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

7.  A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation.

Authors:  Noemí Puig; Javier de la Rubia; Isidro Jarque; Miguel Salavert; Pau Montesinos; Jaime Sanz; Guillermo Martín; Guillermo Sanz; Susana Cantero; Ignacio Lorenzo; Miguel A Sanz
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

Review 8.  Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.

Authors:  Rachel M Greenblatt; Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-21       Impact factor: 3.254

9.  Oral antimicrobial prophylaxis in bone marrow transplant recipients: randomized trial of ciprofloxacin versus ciprofloxacin-vancomycin.

Authors:  C D Ford; W Reilly; J Wood; D C Classen; J P Burke
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999.

Authors:  David M Livermore; Dorothy James; Mark Reacher; Catriona Graham; Thomas Nichols; Peter Stephens; Alan P Johnson; Robert C George
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.